NovaBay Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- NovaBay Pharmaceuticals's estimated annual revenue is currently $7.5M per year.
- NovaBay Pharmaceuticals received $6.0M in venture funding in February 2018.
- NovaBay Pharmaceuticals's estimated revenue per employee is $100,500
- NovaBay Pharmaceuticals's total funding is $52.7M.
Employee Data
- NovaBay Pharmaceuticals has 75 Employees.
- NovaBay Pharmaceuticals grew their employee count by -4% last year.
NovaBay Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Director Physician Sales | Reveal Email/Phone |
NovaBay Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $102.7M | 511 | 25% | N/A | N/A |
#2 | $0.4M | 2 | 0% | N/A | N/A |
#3 | $38.6M | 192 | 3% | N/A | N/A |
#4 | $35M | 127 | 2% | $62.5M | N/A |
#5 | $36.6M | 182 | 18% | N/A | N/A |
#6 | $131.9M | 656 | -3% | N/A | N/A |
#7 | $133.5M | 664 | N/A | N/A | N/A |
#8 | $72.8M | 362 | -4% | N/A | N/A |
#9 | $551.9M | 1716 | -2% | N/A | N/A |
#10 | $11.7M | 58 | 12% | N/A | N/A |
What Is NovaBay Pharmaceuticals?
NovaBay Pharmaceuticals $NBY is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. NovaBay has two distinct product categories: the NEUTROX family of products, led by AVENOVA for the eye care market, NEUTROPHASE® for wound care, and CELLERX for the dermatology market; and AGANOCIDE® compounds, led by AURICLOSENE. NovaBay is commercializing AVENOVA, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction also known as dry eye syndrome. These difficult-to-manage conditions affect approximately 30 million Americans, with an annual market potential that NovaBay estimates at $500 million. NovaBay is gaining market traction with AVENOVA through its 35-medical direct sales representatives under veteran leadership. AVENOVA is available for order in 90% of all pharmacies across the U.S. through distribution agreements with AmerisourceBergen, Cardinal Health and McKesson. www.novabay.com. www.Avenova.com www.neutrophase.com www.celerex.com
keywords:Biotechnology,Healthcare,Household & Personal Products,Personal Products,Pharmaceuticals
$52.7M
Total Funding
75
Number of Employees
$7.5M
Revenue (est)
-4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
NovaBay Pharmaceuticals News
NovaBay Pharmaceuticals (NYSE:NBY) Research Coverage Started at StockNews.com. Posted by admin on Apr 19th, 2022.
NovaBay Pharma (NBY -2.2%) posted lower-than-expected Q4 revenue; Net product revenue for the quarter rose 40% to $2.6 million,...
--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and 12 months ended December 31,...
Other Companies in Emeryville
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $13.7M | 76 | 3% | N/A |
#2 | $19.4M | 80 | 5% | N/A |
#3 | $21.6M | 80 | -1% | N/A |
#4 | $21.9M | 81 | 23% | N/A |
#5 | $36.4M | 84 | 17% | $134M |
NovaBay Pharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2009-08-24 | $2.4M | Undisclosed | Maxim Group LLC | Article |
| 2011-06-30 | $5.2M | Undisclosed | Article | |
| 2012-11-06 | $1.5M | Undisclosed | Pioneer Pharma (Singapore) Pte | Article |
| 2014-03-21 | $6.7M | Undisclosed | Article | |
| 2016-01-08 | $3.0M | Undisclosed | China Kington Asset Management Co. Ltd | Article |
| 2016-03-01 | $2.8M | Undisclosed | Article | |
| 2016-05-24 | $7.8M | Undisclosed | Article | |
| 2016-08-03 | $4.0M | Undisclosed | Article | |
| 2018-02-13 | $6.0M | Undisclosed | OP Financial Investments Limited | Article |